Intellia Therapeutics
NTLA | NASDAQ
$9.86
+$0.16 (+1.65%)
At close: Nov 16, 2026, 4:00 PM ET
$9.80
-$0.06 (-0.61%)
After-hours:
Nov 16, 2026, 7:58 PM ET
Intellia Therapeutics Company Profile
Company profile explainedCompany Profile
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| John Leonard | President, Chief Executive Officer & Director |
| Edward J. Dulac | Executive Vice President, Chief Financial Officer and Treasurer |
| Birgit Schultes | Executive VP & Chief Scientific Officer |
| Derrick J. Rossi | Founder and Member of Scientific Advisor Board |
| Erik J. Sontheimer | Founder and Member of Scientific Advisor Board |
| James E. Basta | Executive Vice President, General Counsel & Corporate Secretary |
| Jennifer A. Doudna | Founder and Member of Scientific Advisor Board |
| Luciano Marraffini | Founder and Member of Scientific Advisor Board |
| Michael Dube | VP & Chief Accounting Officer |
| Rachel E. Haurwitz | Co-Founder |
| Rodolphe Barrangou | Founder and Member of Scientific Advisor Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 4 | Filing |
| Oct 28, 2026 | 3 | Filing |
| Oct 06, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 24, 2026 | 4 | Filing |
Intellia Therapeutics
| Country | United States |
| IPO Date | May 6, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 377 |
| CEO | John Leonard |
Contact Details
40 Erie Street Cambridge,
Massachusetts 02139 United States
Stock Details
| Ticker Symbol | NTLA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001652130 |
| CUSIP Number | 45826J105 |
| ISIN Number | US45826J1051 |
| SIC Code | 2835 |
Recent News
- 4 days ago / seekingalpha.comIntellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript
- 4 days ago / globenewswire.comIntellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
- 10 days ago / seekingalpha.comIntellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision
- 10 days ago / zacks.comIntellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
- 12 days ago / zacks.comIntellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
- 12 days ago / globenewswire.comIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- 13 days ago / globenewswire.comIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
- 14 days ago / globenewswire.comIntellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
- 19 days ago / globenewswire.comIntellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
- 1 month ago / globenewswire.comIntellia Therapeutics Appoints Jing L. Marantz, M.D.
Add to Watchlist
Select watchlists to add or remove NTLA